The PTAB recently limited companies’ ability to utilize the doctrine of sovereign immunity to avoid IPR proceedings. Companies have been assigning their patents to state entities and Tribal governments to protect their IP and attempt to avoid IPR proceedings. The law in this area, however, is in flux, so patent owners may want to reconsider any arrangements with such entities before transferring their patents.
State, Federal, and Tribal governments generally enjoy immunity from lawsuits per the United States Constitution. This means that patents owned by states (e.g., a state university) are immune from IPR proceedings. The same was thought to apply to Tribal governments, but the PTAB just put a halt to this practice.
In 2017, Allergan attempted to avail itself of the doctrine of sovereign immunity by assigning patents already challenged in IPR proceedings to the St. Regis Mohawk Nation (SRMN). The patents covered Allergan’s billion dollar per year blockbuster drug, RESTASIS®. Allergan paid SRMN $13.75 million to transfer the patents. SRMN then granted an exclusive license back to Allergan for up to $15 million per year in royalties. Allergan thought this agreement was a well-spent insurance policy that would protect future profits and Allergan’s patents from IPR proceedings.
The PTAB, however, just ruled that tribal sovereign immunity does not apply to IPR proceedings. Without expressly calling Allergan’s arrangement a sham transaction, the PTAB found that Allergan remains the effective patent owner due to the terms of the exclusive license agreement. The PTAB also side-stepped application of sovereign immunity by reasoning that the Board’s authority is limited to assessing the patentability of the patents, and therefore does not have authority over the patent owner—just the patents.
The law in this area is evolving quickly. Selling patents to Tribal governments to protect against IPR proceedings is no longer a viable option (to the extent it ever was). States still have limited immunity, but the PTAB may start scrutinizing the terms of the transfer agreement before granting immunity. Each transaction is unique, so it is important to fully analyze whether such an arrangement is right for your patents and business.
WHIPgroup is leading counsel for U.S. and international technology companies. We specialize in patent and trademark law.
By Robert D. Keeler There are multiple strategies for addressing Final Office Actions at the USPTO. WHIPgroup already explained why examiners like RCEs (and why you shouldn’t). One alternative to an RCE – an Appeal [Read More…]
Owning Your Brand: Essential Steps For Successful Trademark Protection Walter B. Welsh, Esq., Member 9/20, 10:15 am in Sheraton Grand, Stamford, CT Starting a company? Launching a Product? Re-branding? Securing the right to use and [Read More…]
Protecting Your Business With Strategic Patenting Walter B. Welsh, Esq., Member 9/20, 2:30 pm in Sheraton Grand, Stamford, CT Are you innovating? Launching a new software product? Improving a supplier’s product? Obtaining economically valuable patent [Read More…]